^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
liposomal gemcitabine (FF-10832)
i
Other names: FF-10832, F832
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fujifilm Holdings
Drug class:
DNA polymerase inhibitor
Related drugs:
2ms
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (clinicaltrials.gov)
P1, N=90, Active, not recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
liposomal gemcitabine (FF-10832)
5ms
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (clinicaltrials.gov)
P1, N=90, Recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
liposomal gemcitabine (FF-10832)
11ms
KEYNOTE-B57: A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov)
P2, N=120, Recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | N=10 --> 120
Enrollment change • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • liposomal gemcitabine (FF-10832)
1year
KEYNOTE-B57: A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov)
P2, N=10, Recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | Phase classification: P2a --> P2
Phase classification • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • liposomal gemcitabine (FF-10832)
Share via
